We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Cambridge Cognition Holdings Plc | LSE:COG | London | Ordinary Share | GB00B8DV9647 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 27.50 | 91,379 | 08:00:18 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 27.00 | 28.00 | 28.00 | 27.50 | 27.50 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 13.52M | -3.51M | -0.0836 | -3.29 | 11.53M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 13:58:14 | O | 71,713 | 27.87 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 18/11/2024 | 16:02 | UK RNS | Cambridge Cognition Holdings PLC Holding(s) in Company |
| 06/11/2024 | 07:00 | UK RNS | Cambridge Cognition Holdings PLC Monument Therapeutics secures £1m.. |
| 31/10/2024 | 07:52 | ALNC |  *Cambridge Cognition says AQUA can improve quality assurance for CNS.. |
| 31/10/2024 | 07:00 | UK RNS | Cambridge Cognition Holdings PLC New data demonstrates effectiveness of.. |
| 18/10/2024 | 12:37 | ALNC | EXECUTIVE CHANGES: DFS Furniture CFO lasts 2 years; new Chariot chair |
| 18/10/2024 | 06:00 | UK RNS | Cambridge Cognition Holdings PLC Directorate Change |
| 10/10/2024 | 11:44 | UK RNS | Cambridge Cognition Holdings PLC Block Listing Return |
| 12/9/2024 | 11:38 | UK RNS | Cambridge Cognition Holdings PLC Directorate change |
| 22/8/2024 | 12:42 | ALNC | Cambridge Cognition narrows loss and slashes costs in first half |
| 22/8/2024 | 06:00 | UK RNS | Cambridge Cognition Holdings PLC Interim Results |
Cambridge Cognition (COG) Share Charts1 Year Cambridge Cognition Chart |
|
1 Month Cambridge Cognition Chart |
Intraday Cambridge Cognition Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 01/12/2024 | 10:05 | Cambridge Cognition Holdings (COG) | 795 |
| 02/2/2023 | 20:18 | Dementia - Computerised Neuropsychological Testing | 189 |
| 30/4/2019 | 21:22 | Cambridge Cognition at UK Investor Show | 1 |
| 02/9/2017 | 14:05 | COG with Charts & News | 63 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 14:58:14 | 27.87 | 71,713 | 19,986.41 | O |
| 11:23:35 | 27.30 | 4,666 | 1,273.82 | O |
| 08:20:01 | 27.32 | 15,000 | 4,098.00 | O |
| Top Posts |
|---|
Posted at 03/12/2024 08:20 by Cambridge Cognition Daily Update Cambridge Cognition Holdings Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker COG. The last closing price for Cambridge Cognition was 27.50p.Cambridge Cognition currently has 41,940,413 shares in issue. The market capitalisation of Cambridge Cognition is £11,533,614. Cambridge Cognition has a price to earnings ratio (PE ratio) of -3.29. This morning COG shares opened at 27.50p |
Posted at 19/11/2024 08:41 by bedford1976 Yes Brett Gordon will be in direct contact with the board as a more or less 10 percent part owner. Indicates the share price is an anomaly and the underlying business is on target.I think CamCog is a no brainer at the current share price. Hopefully some more buyers surface and we get a lift in the company value. My fear is we are quite vulnerable to a opportunistic bid with such a low market cap in this lucrative sector. |
Posted at 18/11/2024 10:00 by jasperlachat The price is under the floor! 40% reduction in share price on the only news of Stork being chopped!!? That wasn’t quite the deal back in June, when we handed them more dosh. |
Posted at 18/10/2024 10:50 by nchanning Only problem is running out of cash on AIM is a nightmare at the moment even for the quality growth companies . Just 1.1m net cash at the end of H1 if they don't pull through with a strong H2 the market is going to think there's another placing coming , the share price tanks , then the placing gets done at a discount to the falling price as institutions can name their price in this market . Would almost rather invest at double the market cap with a solid net cash position |
Posted at 18/10/2024 09:18 by bedford1976 Looks like the seller has been cleared now. Hopefully the share price will bounce back now.Agree CamCog is one of the biggest bargains on AIM at the moment. |
Posted at 11/10/2024 12:19 by 40 fathoms Some seem to be misunderstanding the situation. The share price is dropping due to a sizable seller offloading their remaining shares in a tough market. We know who this seller is and how many shares they have left; they will be cleared out soon.Anyone suggesting this is a lifestyle business doesn't understand Cambridge Cognition, the markets it operates in, or its market position. Another point worth making is that the company is likely to signficantly outperform house brokers' profit forecasts for FY 2024 due to the departure of the CEO and CFO in the second half, as well as other unexpected departures that may or may not have contributed to the CEO's exit. There on a run rate basis will reduce costs by a further 800k per year. We are entering the selling season, October to April. If Cambridge Cognition secures a few large contracts, which historically they have done every year for the last 5 or 6 years, the company will be extremely well-positioned. |
Posted at 05/9/2024 12:33 by 40 fathoms This was posted today, no RNS but interesting nonetheless.Don't seem able to post the link, so here is a copy of the text "US patient recruitment firm Splash Clinical has teamed up with UK-based digital brain health services provider Cambridge Cognition (COG) to help sponsors find people to participate in central nervous system (CNS)-focused drug trials. The new partnership – financial terms of which were not disclosed – will see Splash utilize COG’s pre-screening technology to assess potential participants for studies focusing on CNS indications. In a press statement, Splash CEO Matt Teuteberg, said, “By integrating their assessment tools into our platform, we will increase our efficiency in finding the right patients for clinical trials. This partnership will save time and resources for our clients and ultimately make treatments available for patients faster.” CNS recruitment Finding the right patients to take part in drug research is always difficult, nonetheless of the disease involved. Recruiting for trials focusing on neurological disorders is a particular challenge. For example, a 2023 study in the journal Innovations in Clinical Neuroscience suggested the lack of information about CNS patients combined with the nature of the diseases themselves are the issue. “In contrast to other therapeutic areas, such as oncology or cardiovascular diseases, there are no large clinical research networks for CNS, making it more difficult to efficiently reach patients in their care setting. There are also challenges associated with CNS disorders themselves that are not relevant to other therapeutic areas … Thus, the timely recruitment and retention of the right and representative patients is a challenge for CNS clinical trials.” COG’s technology is designed to address such difficulties. The system consists of an online cognitive assessment portal that gathers and processes data from potential study participants. According to the firm, the assessment, which takes around ten minutes, reduces screening failures and increases the quality of patients entering the trial. Splash said that, in combination with its own suite or recruitment tools, the new tech will help it reach a broader population while maintaining high-quality standards. Liam Kaufman, Cambridge Cognition’s vice president of clinical sciences, emphasized the potential benefits of the collaboration, explaining “They’ve got a great recruitment platform and a solid track record in recruitment. Our tools complement their process perfectly. Our goal is to make it easier for researchers to find the right participants for their CNS trials. It’s a win-win for everyone involved.” She added that during a pilot collaboration completed last year, COG’s software helped filter in hard-to-find patients with early Alzheimer’s symptoms. News of the collaboration comes a few months after the Michael J. Fox Foundation began using COG’s technology to identify the cognitive profile of Parkinson’s Disease patients as part of an effort to identify biomarkers – and potential druggable targets – for the condition. |
Posted at 31/8/2024 09:25 by earwacks I remember a few years back a director of an aim company telling me his solicitor advised reporting as a little to the market as possible and preferably nothing at all. Some seem to have turned this in to an absolute art form, others seem to court the market too much. You only have to look at the top holders list in COG to see they are not too bothered with investor relations with PIs. I seem to remember Vox markets or Paul Scot saying they hoped to do an interview with Cog. Presumably too busy or not keen. It does seem that private investor’s frequent trades can mess with the share price on very low volumes. I guess this can become an issue with small companies when trying to raise finance |
Posted at 24/8/2024 11:03 by earwacks @40Fathoms. End of September when the loan note news was made public the share price was @92p. By the time they issued the warrants on October 5th the share price had dropped to low 70s. I think the key is what date the execution of the loan took place. Unless it was written in stone about the 91p looks like the 5 day average weighting was around 74 p. The only thing definite in the September RNS is that the warrants will equate to £540000. About £125000 difference, unfortunate but in the grand scheme maybe not too bad. Probably took them by surprise, as they thought the loan was the better fund raise option. Then all the delays kicked in and we are where we are. I wouldn’t have bought anymore if not for the drop, so in the long run if it works out will be in a better position. Looking back on the mysterious ‘ existing investor’ they took 955000 shares which is about £325,000. So maybe not Claret as I don’t recall them having any shares. Hoping this is one of those IHT free stock. Trouble is good aim companies keep getting taken over, so not a very reliable plan long term! |
Posted at 17/5/2024 12:55 by earwacks Vladim Alexandre , analyst who was with share price Angel has done a recent interview on this stock. He acknowledges the current difficulty in this sector but says a company like COG that once showed 25 per cent growth but still can do 7 percent in a tougher climate is the sign of a very strong company. What is strange is nobody seems to factor in any value of their 25 percent stake in Monument either. Plenty of positives.life science is a pretty nervous market at the moment and volatile, with companies like EKF(I own, Niox my biggest holding and Vrci and Renx which I don’t own yet. Cog, Niox and Ekf I like because they seem to have more control over what they do. The other two seem heavily reliant on what someone else might do for them. The share price fall here is a little unsettling as there appears no obvious reason for it in a market that looks to be getting a little stronger and more stable. |
Posted at 13/10/2023 03:42 by 40 fathoms This link is to an investor day video that was posted today by Cogstate to help investors understand the their cognitive digital trials business. The video is long, so it might something for the weekend viewing.Cogstate is a very similar company to CAMCOG. However, it is further advanced in its commercial development and has a much narrower focus, primarily on Alzheimer's (@70% of revenue) and rare diseases (@10% of revenue). At this point the companies are rarely in direct competition and for both of them their biggest competitors remain the providers of traditional pencil and paper tests. Just to give a sense of the potential size and scope of these markets last year Cogstate put out an estimate that despite being far in the lead in AD they still only had @17% of cognitive testing in the AD trials market. It is also worth noting that CAMCOG is involved with numerous early stage AD trials and will end up with a decent share of the AD market overtime. The video gives a very good overview of the cognitive testing business case and also the huge and deep moat that these companies are able to enjoy. It also shows very clearly how well CAMCOG is positioned in the cognitive trial services ecosystem. CAMCOG is far ahead, both in terms of its technology and the scope of services it is able to offer in to trials. It is also probably also worth mentioning that AD only represents about 15% of the total spend in CNS space. I hold both companies and it is clear that both will grow revenue significantly in the coming 3 or 4 years. However, for CAMCOG specifically we should understand it is about 3 or 4 years behind Cogstate in its move from R&D and validation to commercialisation. Cogstate clearly demonstrates the commercial path and revenue trajectory that we are on. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
